Meralgia Paresthetica Successfully Treated with Palmithoylethanolamide

Rocco Salvatore Calabrò; Carmela Casella; Alfredo Manuli; David Militi; Giuseppe Gervasi

Meralgia Paresthetica Successfully Treated with Palmithoylethanolamide

Innov Clin Neurosci. 2020 Jul 1;17(7-9):10-11.

Authors

Rocco Salvatore Calabrò^{1

2

3

4}, Carmela Casella^{1

2

3

4}, Alfredo Manuli^{1

2

3

4}, David Militi^{1

2

3

4}, Giuseppe Gervasi^{1

2

3

4}

Affiliations

¹ Drs. Calabrò and Manuli are with IRCCS Centro Neurolesi "Bonino Pulejo" in Messina, Italy.
² Dr. Casella is with Policlinico University in Messina, Italy.
³ Dr. Militi is with Stomato-dental Laboratory in Messina, Italy.
⁴ Dr. Gervasi is with the Hygiene and Preventive Medicine Department at the University of Tor Vergata in Rome, Italy.

PMID: 33520398
PMCID: PMC7839659

Abstract

Meralgia paresthetica (MP) is an uncommon entrapment mononeuropathy that is characterized by a sudden onset of paresthesia and numbness in the anterolateral surface of the thigh. Palmithoylethanolamide (PEA) is commonly used in the treatment of chronic pelvic pain and compressive neuropathies. Herein, we describe an otherwise healthy 28-year-old patient affected by posttraumatic MP for three months who was successfully treated with PEA (1200mg/day). Further studies are needed to better investigate the potential use of PEA as therapeutic drug in peripheral neuropathies, including MP, to avoid or delay more invasive surgical treatments.

Keywords: Polyneuropathy; inflammation; nutraceuticals.

Publication types

Case Reports